Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Net Cash Flow (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Net Cash Flow for 4 consecutive years, with $6.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 9.2% to $6.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Dec 2025, down 68.31% year-over-year, with the annual reading at $3.8 million for FY2025, 68.31% down from the prior year.
  • Net Cash Flow for Q4 2025 was $6.3 million at Century Therapeutics, up from -$913000.0 in the prior quarter.
  • The five-year high for Net Cash Flow was $69.6 million in Q1 2022, with the low at -$27.1 million in Q4 2022.
  • Average Net Cash Flow over 4 years is $426562.5, with a median of -$1.2 million recorded in 2022.
  • The sharpest move saw Net Cash Flow surged 221.99% in 2024, then tumbled 1183.79% in 2025.
  • Over 4 years, Net Cash Flow stood at -$27.1 million in 2022, then skyrocketed by 70.53% to -$8.0 million in 2023, then soared by 172.42% to $5.8 million in 2024, then grew by 9.2% to $6.3 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $6.3 million, -$913000.0, and $4.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.